BioCatalystWatch
EXELWorkspace / EXEL / OverviewCompany library
Price
Market cap
Next catalystExpected 2026XB773 — pre-IND development · Trial initiationCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

Zanzalintinib

VEGF receptors × MET

PreINDP1P2P3FilingApproved
Upcoming / outlook

Zanzalintinib

VEGF receptors × MET

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Zanzalintinib

VEGF receptors × MET

PreINDP1P2P3FilingApproved
Upcoming / outlook

Zanzalintinib

VEGF receptors × MET

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

Zanzalintinib

VEGF receptors × MET

PreINDP1P2P3FilingApproved
Upcoming / outlook

Zanzalintinib

VEGF receptors × MET

PreINDP1P2P3FilingApproved
Zanzalintinib

VEGF receptors × MET

PreINDP1P2P3FilingApproved
Zanzalintinib

VEGF receptors × MET

PreINDP1P2P3FilingApproved
Zanzalintinib

VEGF receptors × MET

PreINDP1P2P3FilingApproved
Zanzalintinib

VEGF receptors × MET

PreINDP1P2P3FilingApproved
Zanzalintinib

VEGF receptors × MET

PreINDP1P2P3FilingApproved
Zanzalintinib

VEGF receptors × MET

PreINDP1P2P3FilingApproved
Upcoming / outlook

Zanzalintinib

VEGF receptors × MET

PreINDP1P2P3FilingApproved
Zanzalintinib

VEGF receptors × MET

PreINDP1P2P3FilingApproved
XB371

Tissue factor (TF)

PreINDP1P2P3FilingApproved
XB628

PD-L1 × NKG2A

PreINDP1P2P3FilingApproved

Partner / License out

Mineralocorticoid receptor (MR)

Approved

PreINDP1P2P3FilingApproved

Approved / commercial

Approved

PreINDP1P2P3FilingApproved

Approved

PreINDP1P2P3FilingApproved

Approved

PreINDP1P2P3FilingApproved

Approved

PreINDP1P2P3FilingApproved

History / paused

CDK7

PreINDP1P2P3FilingApproved

CARD11-BCL10-MALT1 complex activation

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

EXEL PR & News

PR & News

EXEL SEC archive